---
title: "Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293796222.md"
description: "Oncolytics Biotech received a Nasdaq notice on July 20, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive days, violating Listing Rule 5550(a)(2). The company has until January 19, 2027, to regain compliance, with a possible 180-day extension. Trading continues under symbol ONCY."
datetime: "2026-07-24T20:43:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293796222.md)
  - [en](https://longbridge.com/en/news/293796222.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293796222.md)
generator: "portal-rs"
---

# Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard

On July 20, 2026, the company received notice from Nasdaq that it failed to maintain the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until January 19, 2027, to regain compliance, with potential for an additional 180 days if conditions are met. Trading continues on the Nasdaq Capital Market under the symbol ONCY.

Original SEC Filing: ONCOLYTICS BIOTECH INC \[ ONCY \] - 8-K - Jul. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)

## Related News & Research

- [Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright](https://longbridge.com/en/news/296357626.md)
- [Oncolytics says FDA aligns on pivotal expansion path for REO 033 colorectal cancer trial](https://longbridge.com/en/news/296232477.md)
- [Fathom Holdings Disclosed Failure to Satisfy a Continued Listing Rule or Standard](https://longbridge.com/en/news/296893303.md)
- [Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard](https://longbridge.com/en/news/296653811.md)
- [Dragonfly Energy Disclosed Failure to Satisfy a Continued Listing Rule or Standard](https://longbridge.com/en/news/296653800.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**